NewsRx

Search our medical news database

Conference Coverage (AACR)

Antisense Therapy Targets Cancer Angiogenesis

Published in Cancer Weekly, May 26th, 1997

Antisense oligodeoxynucleotides (ODNs) targeting the angiogenic molecule, angiogenin (Ang), inhibit the establishment and metastatic spread of tumors in vivo.

Angiogenesis is critical to the growth of solid tumors and the development of metastasis. Interference with the process of tumor-induced angiogenesis has the potential to be an effective therapy for both primary and metastatic cancers. Currently, about nine angiogenic agents are being evaluated in clinical trials for the treatment of several angiogenesis-dependent diseases.

To develop additional angiogenesis inhibitors for cancer therapy, James W. Fett and colleagues from the Harvard Medical...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook